High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma

Bone Marrow Transplantation

Volumn 31, Issue 6, 2003, Pages 441-446

  Rossi, H A ^d   Becker, P S ^d   Emmons, R V B ^d   Westervelt, P ^d   Levy, W ^a   Liu, Q ^b   Clark, Y ^d   Ballen, K ^c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d University of Massachusetts   (United States)

Author keywords

Allogeneic; Carmustine; Conditioning therapy; Non Hodgkin lymphoma; Stem cell transplantation

Indexed keywords

ACICLOVIR; AMPHOTERICIN; ANTIINFECTIVE AGENT; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; ITRACONAZOLE; PREDNISONE; VINCRISTINE;

ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTERSTITIAL PNEUMONIA; LARGE CELL LYMPHOMA; LEUKOCYTE COUNT; LIVER TOXICITY; LUNG TOXICITY; LYMPHOBLASTOMA; MALE; MANTLE CELL LYMPHOMA; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NEUTROPHIL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REVIEW; SEPSIS; T CELL LYMPHOMA; THROMBOCYTE COUNT; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOOD PLATELETS; CARMUSTINE; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; LIVER DISEASES; LUNG DISEASES; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPHILS; RECURRENCE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0242500987     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703874     Document Type: Review

References (44)

1. Chopra R, Goldstone AH, Pearce R et al. Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case controlled analysis of the European Bone Marrow Transplant Group Registry data. J Clin Oncol 1992; 10: 1690-1695.
2. Milpied N, Fielding AK, Pearce RM. Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 1996; 14: 1291-1296.
3. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 1994; 84: 1050-1055.
4. Copelan EA, Kapoor N, Gibbins B et al. Allogeneic marrow transplantation in non-Hodgkin's lymphoma. Bone Marrow Transplant 1990; 5: 47-50.
5. Applebaum FR, Sullivan KM, Buckner CD et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340-1347.
6. Petersen, FB, Appelbaum FR, Hill R et al. Autologous marrow transplantation for malignant lymphoma. A report of 101 cases from Seattle. J Clin Oncol 1990; 8: 638-647.
7. Van Besien K, Sobocinski KA, Rowlings PA et al. Allogeneic bone marrow transplantation for low-grade lymphoma. Blood 1998; 92: 1832-1838.
8. Clift RA, Buckner CD, Appelbaum FR et al. Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens. Blood 1991; 8: 1660-1667.
9. Wheeler C, Khurshid A, Ibrahim J et al. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV). Leuk Lymphoma 2001; 40: 499-509.
10. Kolb HJ, Bender Götze Ch. Late complications after allogeneic bone marrow transplantation for leukemia. Bone Marrow Transplant 1990; 6: 61-67.
11. Gribben JG, Linch JG, and Singer CRJ. Successful treatment of refractory Hodgkin's disease by high-dose combination chemotherapy and autologous bone marrow transplantation. Blood 1989; 73: 340-344.
12. Wheeler C, Antin JH, Churchill WH et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990; 8: 648-656.
13. Gulati SC, Shank B, Black P et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6: 1303-1313.
14. Demirer T, Weaver CH, Buckner CD et al. High-dose cyclophosphamide, carmustine, and etoposide followed by allogeneic bone marrow transplantation in patients with lymphoid malignancies who had received prior dose-limiting radiation therapy. J Clin Oncol 1995; 13: 596-602.
15. Philips GL, Reece DE, Barnett MJ et al. Allogeneic marrow transplantation for refractory Hodgkins disease. J Clin Oncol 1989; 7: 1039-1045.
16. Zander AR, Culbert S, Jagannath S et al. High dose cyclophosphamide, BCNU, and VP-16 (CBV) as a conditioning regimen for allogeneic bone marrow transplantation for patients with acute leukemia. Cancer 1987; 59: 1083-1086.
17. Cheson BD, Horning SJ, Coiffier B et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244-1253.
18. Phillips GL, Reece DE. HLA-identical sibling hematopoietic stem cell transplantation for the non-Hodgkin's lymphomas and Hodgkin's disease. In: Atkinson K (ed.). Clinical Bone Marrow and Blood Stem Cell Transplantation. Cambridge University Press: Cambridge, 2000, pp 500-514.
19. Michallet M, Archimbaud E, Bandini G et al. HLA-identical sibling bone marrow transplantation in younger patient with chronic lymphocytic leukemia. European Group for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry. Ann Int Med 1996; 124: 311-315.
20. Pavletic ZS, Arrowsmith ER, Bierman PJ et al. Outcome of allogeneic stem cell transplantation for B cell chronic lymphocytic leukemia. Bone Marrow Transplant 2000; 25: 717-722.
21. Coiffier B. Which treatment for mantle-cell lymphoma patients in 1998. J Clin Oncol 1998; 16: 3-7.
22. Haas R, Brittinger G, Meusers P et al. Myeloablative therapy with blood stem cell transplantation is effective in mantle cell lymphoma. Leukemia 1996; 10: 1975-1983.
23. Hiddemann W, Dreyling M, Pfreundschuh M et al. Myeloablative radiochemotherapy followed by autologous blood stem cell transplantation leads to a significant prolongation of event-free survival in patients with mantle cell lymphoma (MCL) - results of a prospective randomized European intergroup study. Blood 2001; 98: 861a (absract 3572).
24. Khouri IF, Saliba RM, Younes A et al. Allogeneic transplantation for poor risk mantle cell lymphoma (MCL): chemosensitivity predicts superior outcome. Blood 2001; 98: 416a (abstract 1745).
25. Gianni AM, Bregni M, Siena S et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290-1297.
26. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540-1545.
27. Blume K, Buckner D. Workshop: high dose etoposide containing regimens. Bone Marrow Transplant 1995;15: S207-S212.
28. Wheeler C, Strawderman M, Ayash L et al. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide. J Clin Oncol 1993; 11: 1085-1091.
29. Bierman PJ, Vose JM, Anderson JR et al. High-dose therapy with autologous hematopoietic rescue for follicular low-grade non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 445-452.
30. Stone RM. Myelodysplastic syndrome after autologous bone marrow transplantation for lymphoma: The price of progress? Blood 1994; 83: 3437.
31. Jones RJ, Ambinder RF, Piantadosi S et al. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649-653.
32. Mittenbauer M, Neumeister P, Kalhs P et al. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001; 15: 635-641.
33. Stein RS, Greer JP, Goodman S et al. Intensified preparative regimens and allogeneic transplantation in refractory or relapsed intermediate and high grade non-Hodgkin's lymphoma. Leuk Lymphoma 2001; 41: 343-352.
34. Devergie A, Blaise D, Attal M et al. Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfan-cytoxan versus cytoxan-total body irradiation as preparative regime: a report from the French society of bone marrow graft (SFGM). Blood 1995; 85: 2263-2268.
35. Ringden O, Lapopin M, Tura S et al. A comparison of busulphan versus total body irradiation combined with cyclosphosphaide as conitioning for autograft or allograft bone marrow transplantation in patients with acute leukemia. Br J Haematol 1996; 93: 637-645.
36. Horning S, Chao N, Negrin R et al. The Stanford experience with high-dose etoposide cytoreductive regimens and autologous bone marrow transplantation in Hodgkin's disease and non-Hodgkin's lymphoma: preliminary data. Ann Oncol 1991; 2: 47-50.
37. Williams CD, Goldstone AH, Pearce RM et al. Purging of bone marrow in autologous bone marrow transplantation for non-Hodgkin's lymphoma: a case-matched comparison with unpurged cases by the European Blood and Marrow Transplant Lymphoma Registry. J Clin Oncol 1996; 14: 2454.
38. Van der Jagt RHC, Appelbaum FR, Petersen FR et al. Busulfan and cyclophosphamide as a preparative regimen for bone marrow transplantation in patients with prior chest radiotherapy. Bone Marrow Transplant 1991; 8: 211-215.
39. Reece DE, Barnett MJ, Connors JM et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991;9: 1871-1879.
40. Jagannath S, Dicke DA, Armitage JO et al. High-dose cyclophosphamide, carmustine, and etoposide and autologous bone marrow transplantation for relapsed Hodgkin's disease. Ann Intern Med 1986; 104: 163-168.
41. Chao N, Kastrissios H, Long G et al. A new preparatory regimen for autologous bone marrow transplantation for patients with lymphoma. Cancer 1995; 75: 1354-1359.
42. Haioun C, Lepage E, Gisseelbrecht C et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol - a Groupe d'Etude des Lymphomas de l'Adulte study. J Clin Oncol 2000; 18: 3025-3030.
43. Maris M, Niederwieser D, Sandmaier B. Nonmyeloablative hematopoeitic stem cell transplants (HSCT) using 10/10 HLA antigen matched unrelated donors (URDs) for patients with advanced hematologic malignancies ineligible for conventional HSCT. Blood 2001; 98 (abstract 3563).
44. Mitterbauer M, Neumeister P, Kalhs P et al. Long-term clinical and molecular remission after allogeneic stem cell transplantation (SCT) in patients with poor prognosis non-Hodgkin's lymphoma. Leukemia 2001; 15: 635-641.